The mouse vitronectin receptor is a T cell activation antigen by unknown
ntegrins comprise a complex family of cell adhesion mole-
cules involved in cell-cell and cell-extracellular matrix pro-
tein (ECMP)t interactions (1). At least three subfamilies have
been defined on the basis of the association ofany of a number
of at chains with a common /3 chain (2). We have previously
characterized two mAbs (H9.2B8 and 8.1802) that identified
a novel integrin expressed on murine y/S and a//3 T cell
lines and hybridomas as well as on T cells activated for
prolonged periods of time (7-21 d) by mitogens or alloan-
tigens. This integrin mediated adhesion to fibronectin, vitro-
nectin, and fibrinogen, and the two mAbs in combination,
as well as the tetrapeptide RGDS alone, could inhibit the
binding of cell lines to these ECMP (3). In the present re-
port, we make use of a number of antisera to the vitronectin
receptor (VNR) and demonstrate that this novel integrin is
the murine homologue of the human VNR, thereby demon-
strating for the first time that the VNRis present on mouse
T lymphocytes and that the expression of this (33 integrin
can be upregulated by activation.
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Summary
In this report, we demonstrate that the T cell activation antigen, recognized by monoclonal
antibody HUN, is the murine homologue of the vitronectin receptor (VNR) and, thereby,
we provide initial evidence that VNR is expressed on lymphoid cells. VNR is expressed on a
variety of T cell lines, tumors, and Con A-activated splenocytes, but not resting T cells, and
is capable of binding to the extracellular matrix proteins fibronectin, fibrinogen, and vitronectin,
via the tripeptide sequence RGD. There was no evidence of novel a chains pairing with the
VNRct chain, as has been demonstrated in some human cells. In view of recent studies demon-
strating that this molecule functions as an accessory molecule in T cell activation, the VNR
may play an important role in mouse T cell functions.
Cell Lines.
￿
Dendritic epidermal Tcell (DETC) line T195 and
its corresponding hybridoma (T195/BW) derived from fusion to
BW5147 have been previously described (4-6).
Antibodies.
￿
mAb H9 .2B8 is a hamster mAb obtained after im-
munizations with mouseDETC lines(3). Rabbit anti-human VNR
'Abbreviations used in this paper. DETC, dendritic epidermal T cells;
ECMP, extracellular matrix proteins; NRS, normal rabbit serum; VNR,
vitronectin receptor.
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serum was purchased from Telios Pharmaceuticals, Inc. (LaJolla,
CA). Rabbit antiserumto humanGpIIIa (anti-a3 chain) was agift
from Dr. R. McKever (Oklahoma University, Norman, OK) and
has previously been shown to react with mouse/33integrin chains
(7). Clone M18/2.a.8, secreting rat IgG reactive with mouse 02
integrin chains (8), was purchased from the American Type Cul-
ture Collection (Rockville, MD). Rat mAbto mouseLFA-1 (from
clone M17/5.2) was purchased from Boehringer Mannheim Bio-
chemicals(Indianapolis, IN). mAbH1.2F3, which is reactive with
a T cell activation antigen, has been described previously (9).
Antipeptide Sera.
￿
Rabbit anti-peptide sera against the 000H-
terminal sequences of human (31 (anti-/31) (NPKYEGK) (10) and
VNRachain(antiVNRa) (CEQLQPHENGEGNSET) (11) were
prepared as previously described (12).
Con A Stimulation ofSplenocytes.
￿
Con A-activated spleen cells
from 8-wk-old female C3H/HeNmice were prepared as previously
described (3).
Radioiodination andImmunoprecipitation Analysis.
￿
Cellswere sur-
face labeled with "'I using the previously described lactoperoxi-
dase method (13). Immunoprecipitations andimmunodepletion ex-
periments were performedas previously described(3). Precipitates
were analyzed on SDS-PAGE (7% acrylamide) slab gels in thepres-
ence of 5% 2-ME.
Two-dimensional Electrophoresis.
￿
Nonequilibrium pH gradient
electrophoresis (NEPHGE) was performedaccording to O'Farrell
et al. (14) under nonreducing conditions using pH 4-6.5 ampho-
lines (Pharmacia Fine Chemicals, Piscataway, NJ)in thefirst dimen-
sion and SDS-PAGE (7.% acrylamide) in the second dimension.
Ligand Binding.
￿
Rat fibronectin (Calbiochem-Behring Corp.,
LaJolla, CA), rat fibrinogen (Sigma Chemical Co., St.Louis, MO),
humanvitronectin (Calbiochem-Behring Corp.), and rat collagen
I(Sigma Chemical Co.) were coupledto CNBr-activated Sepharose
4B (Pharmacia Fine Chemicals). Peptide GRGDSPC (Telios Phar-
maceuticals, Inc.) was coupled to thiopropyl-activated Sepharose
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343-3474B (Pharmacia Fine Chemicals) . Magnetic laminin agarose was a
gift from Advanced Magnetics (Cambridge, MA) . Precipitation ex-
perimentswere performedby incubating 250 p,l packed beads with
100 P,1 cell lysate for 60 min room temperature. The beads were
washed in 0.5% NP-40 buffer (3)and integrins eluted with RGDS
peptide (2 mg/ml) in 0.5% NP-40 buffer for 60 min . Immuno-
precipitations using antiVNRet sera were performed with the eluate
as previously described (3) .
Adhesion Assay.
￿
96-well plates (Costar, Cambridge, MA) were
coated with vitronectin (2.0 Rg/ml) by incubating wells overnight
at 37°C and then washing three times with binding buffer (PBS
supplemented with 2.5 mg/ml BSA [Sigma Chemical Co.]) . Re-
maining sites were blocked by adding 200 p .l binding buffer and
incubating for 2 h at 37°C .
RestingT cells andCon A-activated lymphoblasts (10' cells/ml)
were labeled with 300 PCi "Cr (Amersham Corp., Arlington
Heights, IL) for 1 h at 37°C . The cells were then washed with
HBSS and resuspended in 10 ml RPMI supplemented with 10%
FCS for30 min . After two washes, the cells were resuspended (5
x 105/ml) in binding buffer. The cell suspension (100 P.1) was
added to plates precoated with human vitronectin (Telios Phar-
maceuticals, Inc.). Adhesion was evaluated in the presence ofRGDS
or RGES (Peninsula Laboratories, Inc., Belmont, CA) or mAbs
by adding these agents directly to the wells (100 P,1) . After a 2-h
incubation at 37°C, the wells were washed three timeswith binding
buffer. The level of adhesion was subsequently evaluated by the
addition of 200 Al of0.5% Triton X-100 and counting the lysate
in a gamma counter. The percent cell adhesion is expressed as a
percentage ofthe total counts per minute added to the well. Back-
ground binding represents the percent adhesion to plates coated
with albumin alone .
Results and Discussion
mAbHUNRecognizes MouseVNR.
￿
We have previously
shown with DETC cells that mAbs H9.2B8 and 8.18E12
recognize thea chain of an integrin-like heterodimer of 95
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kD (/3 chain) and 140kD (a chain) under nonreducingcon-
ditions, and that, upon reduction, thea chain is cleaved into
116- and 24-kD components (3) . To analyze the relationship
of this heterodimer to other integrins, we performed a series
of sequential immunoprecipitations. Cell lysates (T195 or
T195/BW) were precleared of material reactive with antisera
to (33 orVNRotchains or, as a negative control, normal rabbit
serum (NRS) . These precleared lysates were then immuno-
precipitated with various integrin-reactive antisera followed
by analysis on SDS-PAGE under reducing conditions (Fig.
1) . After preclearing material reactive with NRS, anti-(31
serum precipitated a heterodimer with ana chain of 140 kD
(intense band) and a a chain of 135 kD (faint band) (Fig.
1, lane 2) . Antibody to integrin 02 chains precipitated het-
erodimers of 98 kD (a chain) and 180 kD (a chain) (Fig.
1, lane 3) that were identical in size to the chains precipitated
by a mAb reactive with thea chain of LFA1 (Fig. 1, lane
4) . Threeantisera to theVNR were used . Anti-03 and anti-
VNRci chain sera, as well as antiserum to purified human
VNR, all precipitated a heterodimer with a a chain of 98
kD and an a chain of 116 kD (Fig. 1, lanes 5, 6, and 8) .
The 24-kD component of thea chain can be visualized on
12% acrylamide gels (not shown) . The molecular sizes of
thecomponentVNRchains were similar to thoseofthe inte-
grin recognized by mAb H9.2B8 (Fig. 1, lane 7) .
To determine ifmAbH9.2B8 recognizesVNR, T195/BW
cell lysates were cleared of material reactive with antisera to
(33 chains or VNRci chains by repeated immunoprecipita-
tions. Subsequent precipitations revealed that both anti-a3
andantiVNRctsera cleared theintegrin recognized bymAb
HUN (Fig. 1, B and C), thus proving that mAbHUN
recognizes theVNR. Other immunodepletion experiments
demonstrated thatmAbH9.2B8 precleared thematerial rec-
ognized by antiVNR sera (data not shown) . The process of
Figure 1 .
￿
mAb H9.2B8 recognizes
the vitronectin receptor. Lysates of 1251
cell surface-labeled T195/13W were
precleared by serial immunoprecipita-
tions with antiserum to the 03 chain
or the VNRot chain, or as a negative
control, NRS. Precleared cell lysates
were immunoprecipitated with NRS,
anti-,6,1 chain peptide serum, mAb
M18/2.a.8 to the 02 chain, mAb
M17/5.2 to LFA-1 a chain, anti-,Q3
chain serum, antiVNRcr serum,
anti-human VNR serum, and mAb
H9.2B8. Precipitates were analyzed by
SDS-PAGE with 7% acrylamide under
reducing conditions. The position of
prestained molecular mass markets is in-
dicated on the left . The bands below
the 98-kD molecular mass marker in
lanes 2, 3, 4, 14, and20 are background
bands as evidenced by their presence in
lane 1 . Identical results were obtained
with the parent T195 DETC cell line.Figure 2 .
￿
VNR is expressed by activated T cells. Spleen cells from
C3H/HeN mice were grown in the presence of ConA (3 14g/ml) for
4 dand 11,2 (20 U/ml) for a further 10 d . These, and fresh spleen cells
as nonactivated controls, were surface labeled with 1251and cell lysates im-
munoprecipitated with NRS,mAbM18/2.a.8 to 02 chain, anti-,B3 chain
serum, antiVNRci serum, and anti-humanVNRserum. Immunoprecipi-
rates were analyzed by SDS-PAGE with 7% acrylamide under reducing
conditions. The position ofprestained molecular mass markers is indicated
on the right . The cells that proliferated in response to ConA were found
by FACS analysis to be >95% Thy-1 * .
immunodepletion did not interfere with subsequent im-
munoprecipitations, as 01 integrins (not shown) and LFA1
(Fig. 1, lanes 14 and 20) could still be precipitated from
precleared lysates .
Table 1 .
￿
The Binding of Activated Murine T Cells to Vitronectin Is Inhibited by RGDS and mAb H9.2B8
Day 10 lymphoblasts
Uncultured
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Con A-activated Splenocytes Express VNR .
￿
We have pre-
viously shown by FRCS? analysis that the a chain recog-
nized by mAb H9.2B8 (here shown to be VNRa) is pres-
ent on a population of activated splenocytes (3) . In view
of the fact that VNR has not previously been reported to
be expressed by mouse lymphoid cells, we examined the struc-
ture of the receptor expressed by Con A-activated T cells.
As shown in Fig. 2, no material could be immunoprecipi-
tated from lysates ofresting lymphocytes with the antiVNRct
peptide serum, while the typical LFA-1 heterodimer was seen
with the anti-fl2 precipitate (A) . In contrast, when similar
studies were performed on lysates ofT cells after 14 d of acti-
vation withCon A, all three antiVNR sera immunoprecipi-
tated a 116- and 98-kD dimer (Fig. 2 B) . To determine if
the VNR expressed by the activated splenorytes was func-
tional, quantitative cell attachment studies were performed .
About 30% of splenic T cells activated in vitro with Con
A and 11,2 adhered to wells coated with vitronectin, and this
binding could be completely inhibited by mAb 1-19.2118 and
by the RGDS peptide, but not by the RGES peptide or the
controlmAb H1.2F3 (Table I) . No binding ofresting T cells
to vitronectin-coated plates could be detected .
Previous studies withhumanVNR haveshown theVNR
a chain may associate with (3 chains other than 03, namely
,131 (15, 16), (3x (now named)35) (17), Os (18), and03b (19) .
Some of these novel a chains are not easily distinguished
by their mobilities in one-dimensional SDS-PAGE, but can
be clearly distinguished from 03 chains by pl (17, 19) . To
examine whether some ofthe murine lymphoidVNRa chains
might be associated with chains other than 03, we compared
immunoprecipitations from T195/13W and Con A-activated
splenocytes by NEPHGE analysis (Fig. 3) . It can be seen that
bothT195/13W andCon A-activated splenocytes apparently
express only a single heterodimer when examined after precipi-
tation with anti-a3 or antiVNRct sera, indicating that the
VNR expressed by Con A-activated splenocytes is composed
solely of the VNRa/f3 heterodimer.
VNR Expression by Activated T Cells Bind MultipleECMP .
Integrins have been shown to bind various ECMP (20), and
the key amino acid sequence in many of these binding spe-
cificities has been shown to be the RGD motif (1) . To deter-
mine the specificity of murine VNR, lysates from cells were
reacted withECMP- or RGD-containing peptide coupled to
The results are expressed as the percent cell adhesion . The background binding for the lymphoblasts was 7.3% and for the uncultured cellswas3.8% .
RGDS RGES
Inhibitor (Fig/ml)
H9.2118 H1 .2F3
Media 100 10 100 10 50 5 50 5
32.1 4.5 7.4 29.0 26 .8 7.6 7.3 23.5 23 .5
7.9 4.7 5.9 5.5 4.8 5.5 4.5 5.9 4.7Figure 3 .
￿
NEPHGE analysis ofVNR. T195/BW and Con A-activated
splenocytes were surface labeled with 1251 and cell lysates immunoprecip-
itatedwith anti-(33 serum or antiVNRa serum . Immunoprecipitates were
first separated byNEPHGE usingpH 4-6 .5 ampholines in the first dimen-
sion, then SDS-PAGE with 7% acrylamide under nonreducing conditions
in the second dimension . The position ofprestainedmolecular mass markers
is indicated on the right .
Sepharose beads, eluted with RGDS peptide, and immuno-
precipitated with antiVNRa sera . The results of such anal-
yses shown in Fig. 4 indicate thatVNR from Con A-stimu-
lated splenocytes bound toRGD, fibronectin, fibrinogen, and
vitronectin . Binding to all ligands was blocked by the pres-
ence ofRGDS peptide (data not shown) . A similar binding
pattern was seen withVNR expressed by T195/BW (Fig . 4) .
Our previous studies (3), together with the results of this
report of the mouse VNR, demonstrate that it is similar to
the humanVNR (21) . Both integrins comprise an a chain,
which is cleaved upon reduction, and a /3 chain, which has
an apparently larger molecular mass upon reduction than when
nonreduced, indicative of intrachain disulfide bonds . The
mouseVNR differs from thehumanVNR in that it is capable
of binding to fibronectin in addition to fibrinogen and
vitronectin . Binding to all three ECMP is mediated by the
VNRa//33 heterodimer, and we have not been able to dem-
onstrate any other chains associated withVNRa or /33 that
may contribute to this unique binding specificity . In the case
of human cells, adherence to fibronectin is associated with
VNRa paired with the 01 chain (15, 16) and the /3x chain
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Figure 4.
￿
Binding ofVNR to extracellularmatrix proteins. T195/BW
and Con A-activated splenocytes were cell surface labeled with 1251 and
cell lysates precipitated with fibrinogen, fibronectin, vitronectin, laminin,
or collagen bound to Sepharose 4B . Integrins were eluted with 2 mg/ml
RGDS peptide andimmunoprecipitated withNRS or antiVNRa serum.
Precipitates were analyzed at 7% SDS-PAGE under reducing conditions .
The faint bands of 90, 130, and 170 kD were only seen in precipitates
of material eluted from extracellular matrix protein-coupled beads . Their
identities are currently under investigation . The position ofprestained mo-
lecular mass markers is indicated on the right .
(17, 22) ; however, the VNRa/(31 heterodimer does not
mediate adherence to vitronectin, and the VNRa//3x het-
erodimer does not bind fibrinogen . One possible explana-
tion for the difference is that the studies in man have charac-
terized theVNR on nonlymphoid cells, whereas our studies
in the mouse have characterized aVNR found on lymphoid
cells.
Previous studies haveshown that activation is required for
integrin expression and/or function onT lymphocytes. Inte-
grins that are expressed constitutively are only able to bind
their ligand after T cell activation (20, 23-25), whereas inte-
grins not normally expressed by restingT cells, such asVLA1
and VLA2, are induced afterT cell activation. In this study,
we have shown that only activated murine T cells express
the VNR. These results differ from those of Klingemann
and Dedhar (26), who demonstrated VNR expression on
resting human T cells. Although a species difference in the
regulation of expression of theVNR on lymphoid cells may
exist, these latter studies were performed with polyclonal an-
tisera to thehumanVNR and have not, as yet, been confirmed
with mAbs.
The function ofVNR on activated T lymphocytes is still
unclear; however, it seems likely that VNR functions as a
costimulatory molecule (27), as has been recently described
for several other integrins (LFA-1, VLA-4, -5, -6) (23-25) .References
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